Clinical Trial Update: Study to Evaluate Immunogenicity of the Hepatitis B Antigen of the GSK Biologicals' Candidate Malaria Vaccine (257049) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating immunogenicity of the Hepatitis B antigen of GSK's candidate malaria vaccine has completed with results posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malaria

Drugs mentioned

• GSK Malaria Vaccine (candidate 257049) (malaria vaccine candidate 257049)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Malaria, Malaria Vaccines | Phase 3 | Status: COMPLETED | Results posted: 2014-02-10